ENANTA PHARMACEUTICALS, INC Federal Income Tax Expense (Benefit), Continuing Operations
ENANTA PHARMACEUTICALS, INC (ENTA) reported Federal Income Tax Expense (Benefit), Continuing Operations of $28.72 million for the 12-month period ending 2021-09-30, per its 10-K filed 2021-11-24.
Discontinued › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2021-11-24
- ENANTA PHARMACEUTICALS, INC federal income tax expense (benefit), continuing operations for fiscal 2021 was $28.72M, a 234.70% increase from fiscal 2020.
- ENANTA PHARMACEUTICALS, INC federal income tax expense (benefit), continuing operations for fiscal 2020 was $8.58M.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2021-09-30 | $28.72M 10-K · filed 2021-11-24 |
| 2020-09-30 | $8.58M 10-K · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |